{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:41Z","timestamp":1791314381667,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-CE13-0037"],"award-info":[{"award-number":["ANR-14-CE13-0037"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007423","name":"Duchenne Parent Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00c3\u00a7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00c3\u00a9 et de la Recherche M\u00c3\u00a9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.omtn.2017.06.013","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T15:01:44Z","timestamp":1498143704000},"page":"144-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model"],"prefix":"10.1016","volume":"8","author":[{"given":"Karima","family":"Relizani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Zarrouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Vaillend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Leumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Goyenvalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2017.06.013_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2017.06.013_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2017.06.013_bib3","series-title":"Duchenne Muscular Dystrophy","author":"Emery","year":"2003"},{"key":"10.1016\/j.omtn.2017.06.013_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2017.06.013_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00281062","article-title":"Population data on benign and severe forms of X-linked muscular dystrophy","volume":"75","author":"Mostacciuolo","year":"1987","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2017.06.013_bib7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2017.06.013_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2017.06.013_bib10","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/mtna.2014.6","article-title":"What can we learn from clinical trials of exon skipping for DMD?","volume":"3","author":"Lu","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2017.06.013_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","article-title":"Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy","volume":"15","author":"Straub","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2017.06.013_bib12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice","volume":"24","author":"Stein","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2017.06.013_bib13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JND-160146","article-title":"Therapeutic potential of Tricyclo-DNA antisense oligonucleotides","volume":"3","author":"Goyenvalle","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.omtn.2017.06.013_bib15","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1021\/ja025569+","article-title":"Watson-Crick base-pairing properties of tricyclo-DNA","volume":"124","author":"Renneberg","year":"2002","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2017.06.013_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/nar\/gkq733","article-title":"Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes","volume":"39","author":"Ittig","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib17","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib18","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1093\/nar\/gks273","article-title":"TricycloDNA-modified oligo-2\u2032-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry","volume":"40","author":"Murray","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib19","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2017.06.013_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0192623313505781","article-title":"Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide","volume":"42","author":"Frazier","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2017.06.013_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2014.1500","article-title":"Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges","volume":"24","author":"Aartsma-Rus","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2017.06.013_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jgm.295","article-title":"Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy","volume":"4","author":"Mann","year":"2002","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: a point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.omtn.2017.06.013_bib25","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.200503-322OC","article-title":"Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy","volume":"172","author":"Kohler","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omtn.2017.06.013_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0306-4522(93)90392-S","article-title":"The distribution of dystrophin in the murine central nervous system: an immunocytochemical study","volume":"54","author":"Lidov","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.omtn.2017.06.013_bib27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q","article-title":"Differential expression of utrophin and dystrophin in CNS neurons: an in\u00a0situ hybridization and immunohistochemical study","volume":"422","author":"Knuesel","year":"2000","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.omtn.2017.06.013_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13229-015-0053-9","article-title":"Altered social behavior and ultrasonic communication in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy","volume":"6","author":"Miranda","year":"2015","journal-title":"Mol. Autism"},{"key":"10.1016\/j.omtn.2017.06.013_bib29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/brain\/awn253","article-title":"A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice","volume":"132","author":"Sekiguchi","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2017.06.013_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2017.06.013_bib31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","article-title":"Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide","volume":"2","author":"Henry","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2017.06.013_bib32","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/nbt1042","article-title":"Role of Toll-like receptors in antisense and siRNA [corrected]","volume":"22","author":"Agrawal","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2017.06.013_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.2013.774366","article-title":"Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides","volume":"13","author":"Dirin","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2017.06.013_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","article-title":"Biomarkers of acute kidney injury","volume":"48","author":"Vaidya","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2017.06.013_bib36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.toxrep.2015.05.008","article-title":"The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.omtn.2017.06.013_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2017.06.013_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/nar\/gkh187","article-title":"Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA","volume":"32","author":"Ittig","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nlm.2015.07.006","article-title":"Cognitive dysfunction in the dystrophin-deficient mouse model of Duchenne muscular dystrophy: a reappraisal from sensory to executive processes","volume":"124","author":"Chaussenot","year":"2015","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.omtn.2017.06.013_bib40","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1093\/nar\/gkv857","article-title":"In silico and in\u00a0vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization","volume":"43","author":"Kamola","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.06.013_bib41","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nbt.2376","article-title":"Assessing unintended hybridization-induced biological effects of oligonucleotides","volume":"30","author":"Lindow","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2017.06.013_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/toxsci\/kfm260","article-title":"Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium","volume":"101","author":"Zhou","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtn.2017.06.013_bib43","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/hmg\/dds082","article-title":"Rescue of severely affected dystrophin\/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping","volume":"21","author":"Goyenvalle","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2017.06.013_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00467-011-2001-z","article-title":"Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in mice","volume":"27","author":"Mattison","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.omtn.2017.06.013_bib45","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/ddg100","article-title":"Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients","volume":"12","author":"Aartsma-Rus","year":"2003","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:24:33Z","timestamp":1761873873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117301993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":45,"alternative-id":["S2162253117301993"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2017.06.013","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2017.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors.","name":"copyright","label":"Copyright"}]}}